The Proclaimsm (Proleukin® Observational Study to Evaluate Treatment Patterns and Clinical Response in Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy

被引：0

作者：

Kaufman, Howard ^{[1
]}

McDermott, David ^{[2
]}

Morse, Michael ^{[3
]}

Lowder, James ^{[4
]}

Wong, Michael ^{[5
]}

机构：

[1] Rush Univ, Chicago, IL 60612 USA

[2] Harvard Univ, Boston, MA 02115 USA

[3] Duke Univ, Durham, NC USA

[4] Prometheus Labs Inc, San Diego, CA USA

[5] Univ So Calif, Los Angeles, CA USA

来源：

JOURNAL OF IMMUNOTHERAPY | 2012年 / 35卷 / 09期

关键词：

Interleukin-2; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：749 / 750

页数：2

共 29 条

[21] Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study
Sonata Jarmalaite
Rasa Andrekute
Asta Scesnaite
Kestutis Suziedelis
Kirsti Husgafvel-Pursiainen
Feliksas Jankevicius
Journal of Cancer Research and Clinical Oncology, 2010, 136 : 847 - 854
[22] Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study
Jarmalaite, Sonata
Andrekute, Rasa
Scesnaite, Asta
Suziedelis, Kestutis
Husgafvel-Pursiainen, Kirsti
Jankevicius, Feliksas
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) : 847 - 854
[23] Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients
Bright, Richard
Coventry, Brendon J.
Eardley-Harris, Nathan
Briggs, Nancy
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (01) : 21 - 30
[24] Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience
Saraceni, Christine
Agostino, Nicole
Weiss, Michael J.
Harris, Katherine
Nair, Suresh
SPRINGERPLUS, 2015, 4
[25] Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
Bulgarelli, Jenny
Piccinini, Claudia
Petracci, Elisabetta
Pancisi, Elena
Granato, Anna Maria
de Rosa, Francesco
Guidoboni, Massimo
Petrini, Massimiliano
Ancarani, Valentina
Foschi, Giovanni
Romeo, Antonino
Tontini, Luca
De Giorgi, Ugo
Lolli, Cristian
Gentili, Giorgia
Valmorri, Linda
Rossi, Alice
Ferroni, Fabio
Casadei, Carla
Cortesi, Pietro
Crudi, Laura
Ridolfi, Laura
FRONTIERS IN IMMUNOLOGY, 2021, 12
[26] High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study
Pardo, N
Marti, F
Fraga, G
Illa, J
Badell, I
Peiro, M
Bertran, E
Garcia, J
Rueda, F
Cubells, J
MEDICAL AND PEDIATRIC ONCOLOGY, 1996, 27 (06): : 534 - 539
[27] Effects of hCG and beta-hCG on IL-2 and sIL-2R secretion from human peripheral blood mononuclear cells: A dose-response study in vitro
Komorowski, J
Gradowski, G
Stepien, H
IMMUNOLOGY LETTERS, 1997, 59 (01) : 29 - 33
[28] Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study
Truman, Lucy A.
Pekalski, Marcin L.
Kareclas, Paula
Evangelou, Marina
Walker, Neil M.
Howlett, James
Mander, Adrian P.
Kennet, Jane
Wicker, Linda S.
Bond, Simon
Todd, John A.
Waldron-Lynch, Frank
BMJ OPEN, 2015, 5 (12):
[29] High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - A retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006
Klapper, Jacob A.
Downey, Stephanie G.
Smith, Franz O.
Yang, James C.
Hughes, Marybeth S.
Kammula, Udai S.
Sherry, Richard M.
Royal, Richard E.
Steinberg, Seth M.
Rosenberg, Steven
CANCER, 2008, 113 (02) : 293 - 301

← 1 2 3 →